Greenphire and Ernst & Young Announce Strategic Partnership
News Jul 10, 2013
Greenphire has announced the launch of a strategic partnership with Ernst & Young. The partnership will combine Greenphire’s industry leading eClinicalGPS technology with the global intellectual property and expertise of Ernst & Young’s advisory practice for clients in the pharmaceutical industries.
Within the scope of the partnership, Greenphire’s clients will have access to specialists within Ernst & Young’s global consulting and advisory practice that focuses on global HCP transparency regulatory compliance (e.g. - The US Sunshine Act).
This relationship will increase the strength of Greenphire’s eClinicalGPS technology by giving clients the ability to leverage Ernst & Young’s market leading advisory practice in concert with Greenphire’s market leading payment and data aggregation technology.
Ernst & Young’s advisory practice will further assist Greenphire’s clients to comply with 75+ transparency regulations globally.
Additionally, Ernst & Young’s extensive proprietary research will be routed into a new Greenphire technology solution. The technology, currently in development, will be a first-of-its-kind, web-based SaaS solution to manage and track all transactional interactions between pharmaceutical companies and HCPs, including cash transactions and transfers of value, on a global basis across all aspects of pharmaceutical operations.
Sam Whitaker, co-founder and CEO of Greenphire, comments: "We are delighted to work with Ernst & Young in what is sure to be an industry-changing partnership. Global transparency regulations are constantly evolving, and our clients are very much in need of a reliable source of information on how to adjust their processes to remain compliant. We are very excited to be able to offer them access to an incredible resource such as Ernst & Young.”
Martin Holyoake, Partner at Ernst & Young said: “We are proud to be working with Greenphire to help ensure that clients successfully navigate the complicated legislative landscape and deliver value. The deep technical knowledge and grounded relationships formed as a result of our long standing presence in this sector will help clients translate regulation, meet their obligations and gain real insight. We look forward to working with Greenphire to bring tangible benefits to our clients.”
Arsenic Trioxide Could Extend Lives of Patients with Aggressive Brain CancerNews
Arsenic trioxide could be a powerful therapy that could extend the lives of certain glioblastoma patients by as much as three to four times the median expectation.READ MORE
XenoGesis and Juniper Pharma Services Strengthen AllianceNews
Campanies extend strategic alliance in early drug development services.READ MORE
Quotient Clinical Signs Cocrystal Agreement with NuformixNews
Partnership to evaluate cocrystal formulations using translational pharmaceutics.READ MORE
Comments | 0 ADD COMMENT
Annual Conference on Antimicrobials and Drug Resistance
Sep 24 - Sep 25, 2018
1st Alpine Winter Conference on Medicinal and Synthetic Chemistry
Jan 28 - Feb 01, 2018